OraSure Technologies up 5% on FDA Approval

OraSure Technologies

is trading higher after it resumed trading. The stock was halted due to the announcement of FDA approval for OraSure's In-Home HIV Test earlier today. Douglas A. Michels, President and Chief Executive Officer of OraSure Technologies said, "Approval of the OraQuick® In-Home HIV Test represents a major breakthrough in HIV testing. For the first time ever, individuals will have access to an in-home oral test that will empower them to learn their HIV status in the comfort of their home and obtain referral to care if needed. This new in-home rapid test – the same test doctors have used for years – will help individuals at risk for HIV who otherwise may not test in a professional or clinical setting." OraSure Technologies is currently trading at $12.15, a gain of $0.65 or 5.65%.